BCYC
Price
$8.70
Change
+$0.20 (+2.35%)
Updated
Jun 6, 04:09 PM (EDT)
Capitalization
589.35M
55 days until earnings call
RCUS
Price
$9.89
Change
+$0.26 (+2.70%)
Updated
Jun 6, 11:10 AM (EDT)
Capitalization
1.02B
55 days until earnings call
Interact to see
Advertisement

BCYC vs RCUS

Header iconBCYC vs RCUS Comparison
Open Charts BCYC vs RCUSBanner chart's image
Bicycle Therapeutics
Price$8.70
Change+$0.20 (+2.35%)
Volume$786
Capitalization589.35M
Arcus Biosciences
Price$9.89
Change+$0.26 (+2.70%)
Volume$300
Capitalization1.02B
BCYC vs RCUS Comparison Chart
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. RCUS commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Buy and RCUS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (BCYC: $8.51 vs. RCUS: $9.63)
Brand notoriety: BCYC and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 55% vs. RCUS: 51%
Market capitalization -- BCYC: $589.35M vs. RCUS: $1.02B
BCYC [@Biotechnology] is valued at $589.35M. RCUS’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, BCYC is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 6 TA indicator(s) are bullish while RCUS’s TA Score has 5 bullish TA indicator(s).

  • BCYC’s TA Score: 6 bullish, 2 bearish.
  • RCUS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, BCYC is a better buy in the short-term than RCUS.

Price Growth

BCYC (@Biotechnology) experienced а -2.18% price change this week, while RCUS (@Biotechnology) price change was +1.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.55%. For the same industry, the average monthly price growth was +17.24%, and the average quarterly price growth was +3.49%.

Reported Earning Dates

BCYC is expected to report earnings on Jul 31, 2025.

RCUS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+11.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($1.02B) has a higher market cap than BCYC($589M). RCUS YTD gains are higher at: -35.326 vs. BCYC (-39.214). BCYC has higher annual earnings (EBITDA): -200.61M vs. RCUS (-377M). RCUS has more cash in the bank: 997M vs. BCYC (793M). BCYC has less debt than RCUS: BCYC (8.33M) vs RCUS (60M). RCUS has higher revenues than BCYC: RCUS (141M) vs BCYC (25.7M).
BCYCRCUSBCYC / RCUS
Capitalization589M1.02B58%
EBITDA-200.61M-377M53%
Gain YTD-39.214-35.326111%
P/E RatioN/AN/A-
Revenue25.7M141M18%
Total Cash793M997M80%
Total Debt8.33M60M14%
FUNDAMENTALS RATINGS
BCYC vs RCUS: Fundamental Ratings
BCYC
RCUS
OUTLOOK RATING
1..100
1415
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9092
PRICE GROWTH RATING
1..100
9063
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
3445

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (22) in the null industry is in the same range as RCUS (53) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to RCUS’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to RCUS’s over the last 12 months.

BCYC's SMR Rating (90) in the null industry is in the same range as RCUS (92) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's Price Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as BCYC (90) in the null industry. This means that RCUS’s stock grew similarly to BCYC’s over the last 12 months.

RCUS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as BCYC (100) in the null industry. This means that RCUS’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCRCUS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 17 days ago
87%
Bearish Trend 24 days ago
83%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGITX14.960.03
+0.23%
Baillie Gifford International Alpha 2
LCCAX35.63N/A
N/A
Columbia Contrarian Core A
PNBCX27.45N/A
N/A
Virtus NFJ Large-Cap Value C
SLCAX15.57N/A
N/A
SEI Large Cap A (SIIT)
VICVX24.21N/A
N/A
USA Mutuals Vice Institutional

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with INO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+0.59%
INO - BCYC
57%
Loosely correlated
N/A
XNCR - BCYC
54%
Loosely correlated
+0.22%
RLAY - BCYC
51%
Loosely correlated
N/A
RPTX - BCYC
51%
Loosely correlated
+2.76%
RCUS - BCYC
45%
Loosely correlated
+0.31%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with ACLX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+0.31%
ACLX - RCUS
49%
Loosely correlated
+1.18%
XNCR - RCUS
48%
Loosely correlated
+0.22%
IMNM - RCUS
47%
Loosely correlated
+1.16%
APGE - RCUS
47%
Loosely correlated
+3.10%
TRDA - RCUS
46%
Loosely correlated
+2.14%
More